Xiaofeng Du

Xiaofeng Du

Auto-generated profile, based on publicly available information

Xiaofeng Du

Commonwealth Scientific and Industrial Research Organisation, Agriculture & Food, Brisbane, QLD 4072, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JLJian Liu
Jian Liu
DDDave Dyer
Dave Dyer
Jipeng WangJipeng Wang
Jipeng Wang
Shuqi WangShuqi Wang
Shuqi Wang
XDXiaofeng Du
Xiaofeng Du
Wei HuWei Hu
Wei Hu
Schistosomiasis is a disease caused by parasitic worms and more than 200 million people are infected worldwide. The emergence of resistance to the most commonly used drug, praziquantel (PZQ), makes the development of novel drugs an urgent task. 3-oxoacyl-ACP reductase (OAR), a key enzyme involved in the fatty acid synthesis pathway, has been identified as a potential drug target against many pathogenic organisms. However, no research on Schistosoma japonicum OAR (SjOAR) has been reported. The characterization of the SjOAR protein will provide new strategies for screening antischistosomal drugs that target SjOAR. After cloning the SjOAR gene, recombinant SjOAR protein was purified and assayed for enzymatic activity. The tertiary structure of SjOAR was obtained by homology modeling and 27 inhibitor candidates were identified from 14,400 compounds through molecular docking based on the structure. All of these compounds were confirmed to be able to bind to the SjOAR protein by BIAcore analysis. Two compounds exhibited strong antischistosomal activity and inhibitory effects on the enzymatic activity of SjOAR. In contrast, these two compounds showed relatively low toxicity towards host cells. The work presented here shows the feasibility of isolation of new antischistosomal compounds using a combination of virtual screening and experimental validation. Based on this strategy, we successfully identified 2 compounds that target SjOAR with strong antischistosomal activity but relatively low cytotoxicity to host cells.

1 May 2023 in Current Genomics
Verified
Journal Article
Open access
PDF file
XDXiaofeng Du
Xiaofeng Du
DMDonald P. McManus
Donald P. McManus
JFJuliet D. French
Juliet D. French
HSHaran Sivakumaran
Haran Sivakumaran
RJRebecca L. Johnston
Rebecca L. Johnston
HYHong You
Hong You
Background: Recent studies on CRISPR/Cas9-mediated gene editing in Schistosoma mansoni have shed new light on the study and control of this parasitic helminth. However, the gene editing efficiency in this parasite is modest. Methods: To improve the efficiency of CRISPR/Cas9 genome editing in schistosomes, we used lentivirus, which has been effectively used for gene editing in mammalian cells, to deliver plasmid DNA encoding Cas9 nuclease, a sgRNA targeting acetylcholinesterase (SmAChE) and a mCherry fluorescence marker into schistosomes. Results: MCherry fluorescence was observed in transduced eggs, schistosomula, and adult worms, indicating that the CRISPR components had been delivered into these parasite stages by lentivirus. In addition, clearly changed phenotypes were observed in SmAChE-edited parasites, including decreased SmAChE activity, reduced hatching ability of edited eggs, and altered behavior of miracidia hatched from edited eggs. Next-generation sequencing analysis demonstrated that the lentiviral transductionbased CRISPR/Cas9 gene modifications in SmAChE-edited schistosomes were homology-directed repair predominant but with much lower efficiency than that obtained using electroporation (data previously published by our laboratory) for the delivery of CRISPR components. Conclusion: Taken together, electroporation is more efficient than lentiviral transduction in the delivery of CRISPR/Cas9 into schistosomes for programmed genome editing. The exploration of tactics for enhancing CRISPR/Cas9 gene editing provides the basis for the future improvement of programmed genome editing in S. mansoni.

6 August 2025 in Gene
Verified
Journal Article
Closed access
XDXiaofeng Du
Xiaofeng Du
AQAlexander Quinn
Alexander Quinn
MMMoira Menzies
Moira Menzies
LPLaercio R. Porto-Neto
Laercio R. Porto-Neto

17 August 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
XDXiaofeng Du
Xiaofeng Du
DMDonald P. McManus
Donald P. McManus
JFJuliet D. French
Juliet D. French
NCNatasha Collinson
Natasha Collinson
HSHaran Sivakumaran
Haran Sivakumaran
HYHong You
Hong You
Employing the flatworm parasite Schistosoma mansoni as a model, we report the first application of CRISPR interference (CRISPRi) in parasitic helminths for loss-of-function targeting the SmfgfrA gene which encodes the stem cell marker, fibroblast growth factor receptor A. SmFGFRA is essential for maintaining schistosome stem cells and critical in the schistosome-host interplay. The SmfgfrA gene was targeted in S. mansoni adult worms, eggs and schistosomula using a catalytically dead Cas9 (dCas9) fused to a transcriptional repressor KRAB. We showed that SmfgfrA repression resulted in considerable phenotypic differences in the modulated parasites compared with controls, including reduced levels of SmfgfrA transcription and decreased protein expression of SmFGFRA, a decline in EdU (thymidine analog 5-ethynyl-2’-deoxyuridine, which specifically stains schistosome stem cells) signal, and an increase in cell apoptosis. Notably, reduced SmfgfrA transcription was evident in miracidia hatched from SmfgfrA -repressed eggs, and resulted in a significant change in miracidial behavior, indicative of a durable repression effect caused by CRISPRi. Intravenous injection of mice with SmfgfrA -repressed eggs resulted in granulomas that were markedly reduced in size and a decline in the level of serum IgE, emphasizing the importance of SmFGFRA in regulating the host immune response induced during schistosome infection. Our findings show the feasibility of applying CRISPRi for effective, targeted transcriptional repression in schistosomes, and provide the basis for employing CRISPRi to selectively perturb gene expression in parasitic helminths on a genome-wide scale.

9 March 2025 in Biocatalysis and Agricultural Biotechnology
Verified
Journal Article
Open access
XDXiaofeng Du
Xiaofeng Du
AQAlexander Quinn
Alexander Quinn
TMTim Mahony
Tim Mahony
DXDi Xia
Di Xia
LPLaercio R. Porto-Neto
Laercio R. Porto-Neto

17 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
XDXiaofeng Du
Xiaofeng Du
AQAlexander Quinn
Alexander Quinn
LNLaercio R. Porto Neto
Laercio R. Porto Neto
We developed a CRISPR/dCas9-based biosensor platform for the detection of specific DNA sequences. In this biosensor, two high-fidelity (HiFi) dCas9 proteins were fused to either of the complementary NanoLuc fragments (SmBiT and LgBiT). Luminescence was generated upon colocalization of the two HiFi dCas9 fusion proteins to target sites. We applied this biosensor to detect two Y-chromosome genes in Bos taurus: multicopy TSPY (testis-specific protein, Y-encoded) and single-copy SRY (sex determining region Y). Two TSPY-sensors and one SRY-sensor were designed for gene detection. The specific DNA binding ability of the biosensor was confirmed by electrophoresis mobility shift assay and in vitro luciferase assays. TSPY-sensor1, with an interspace of 23 bp and a concentration of 20 nM, demonstrated the highest signal-to-background ratio (8-fold) in vitro. Similarly, SRY-sensor yielded 7.6-fold higher amount of luminescence than the control group in vitro. However, in cells, TSPY sensors yielded significantly higher signal-to-background ratio (8-fold) than SRY sensor (4.7-fold), suggesting a potential advantage of targeting multicopy genes for enhanced biosensor sensitivity in live-cell applications. These findings demonstrate the feasibility of using this biosensor platform for detecting specific gene sequences in vitro and in live cells.